Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Agile Therapeutics Inc    AGRX

AGILE THERAPEUTICS INC (AGRX)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Agile Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference

share with twitter share with LinkedIn share with facebook
share via e-mail
0
09/14/2017 | 01:46pm CEST

PRINCETON, N.J., Sept. 14, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq:AGRX), a women’s health specialty pharmaceutical company, announced today that Al Altomari, Chairman and CEO, will present at the Cantor Fitzgerald Global Healthcare Conference on Tuesday, September 26th, 2017 at 11:30 AM Eastern Time in New York City.

To access the live and archived webcast of the presentation, visit the Investor Relations section of Agile Therapeutics website at www.agiletherapeutics.com.  The webcast will be archived on Agile Therapeutics website for 60 days following the event.

About Agile Therapeutics
Agile Therapeutics is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today’s women. Our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Our lead product candidate, Twirla®, (ethinyl estradiol and levonorgestrel transdermal system), also known as AG200-15, is a once-weekly prescription contraceptive patch that recently completed Phase 3 trials. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to provide advantages over currently available patches and is intended to optimize patch adhesion and patient wearability. For more information, please visit the company website at www.agiletherapeutics.com. Follow Agile on Twitter: @agilether. The company may occasionally disseminate material, nonpublic information on the company website.

About Twirla®
Twirla (ethinyl estradiol and levonorgestrel transdermal system) or AG200-15 is an investigational once-weekly prescription contraceptive patch. AG200-15 is a combined hormonal contraceptive (CHC) patch that contains the active ingredients ethinyl estradiol (EE), a synthetic estrogen, and levonorgestrel (LNG), a type of progestin, a synthetic steroid hormone. Twirla is designed to be applied once weekly for three weeks, followed by a week without a patch.

Contact: 
Mary Coleman - 609-683-1880
Investor Relations, Agile Therapeutics, Inc.

Primary Logo


© GlobeNewswire 2017
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on AGILE THERAPEUTICS INC
05/25AGILE THERAPEUTICS : Patent Application Titled "Contraceptive Compositions and M..
AQ
05/22AGILE THERAPEUTICS : Provides Regulatory Update on Twirla for the Prevention of ..
AQ
05/21AGILE THERAPEUTICS INC : Today’s Research Reports on Stocks to Watch: Agile Ther..
AC
05/18AGILE THERAPEUTICS INC : Other Events, Financial Statements and Exhibits (form 8..
AQ
05/18Agile Therapeutics, Inc. Provides Regulatory Update on Twirla® (AG200-15) for..
GL
05/17AGILE THERAPEUTICS : New Phase III Data Show Agile Therapeutics' Low-Dose Patch ..
AQ
05/11AGILE THERAPEUTICS : Reports First Quarter 2018 Financial Results
AQ
05/07AGILE THERAPEUTICS : 1Q Earnings Snapshot
AQ
05/07AGILE THERAPEUTICS : Management's Discussion and Analysis of Financial Condition..
AQ
05/07AGILE THERAPEUTICS INC : Results of Operations and Financial Condition, Financia..
AQ
More news
News from SeekingAlpha
05/24INSTITUTIONAL TOP IDEAS SERIES : Perceptive Advisors 
05/21Agile Therapeutics Is Attempting A Hail Mary Play With A Formal Dispute Resol.. 
05/21YOUR DAILY PHARMA SCOOP : Abeona Presents Strong Data, Glaxo Nucala Treatment Be.. 
05/18Midday Gainers / Losers (05/18/2018) 
05/18HEALTHCARE - TOP 5 GAINERS / LOSERS : 10 am (05/18/2018) 
Financials ($)
Sales 2018 5,50 M
EBIT 2018 -25,4 M
Net income 2018 -25,8 M
Debt 2018 -
Yield 2018 -
P/E ratio 2018 -
P/E ratio 2019
Capi. / Sales 2018 3,67x
Capi. / Sales 2019 1,71x
Capitalization 20,2 M
Chart AGILE THERAPEUTICS INC
Duration : Period :
Agile Therapeutics Inc Technical Analysis Chart | AGRX | US00847L1008 | 4-Traders
Technical analysis trends AGILE THERAPEUTICS INC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 6
Average target price 5,60 $
Spread / Average Target 849%
EPS Revisions
Managers
NameTitle
Alfred F. Altomari President, Chief Executive Officer & Director
Scott M. Coiante Chief Financial Officer & Vice President
Elizabeth Ijeoma Onyemelukwe Garner Chief Medical Officer & Senior Vice President
Abhijeet J. Lele Independent Director
William T. McKee Director
Sector and Competitors
1st jan.Capitalization (M$)
AGILE THERAPEUTICS INC-77.14%20
GILEAD SCIENCES-5.60%87 612
VERTEX PHARMACEUTICALS4.75%40 136
REGENERON PHARMACEUTICALS-21.64%31 122
GENMAB15.89%11 430
BEIGENE LTD (ADR)94.13%10 161